netupitant-palonosetron
Selected indexed studies
- Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting. (Drugs, 2021) [PMID:34292534]
- Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice. (Curr Cancer Drug Targets, 2022) [PMID:35570542]
- Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting. (Drugs, 2015) [PMID:26613606]
_Worker-drafted node — pending editorial review._
Connections
netupitant-palonosetron is a side effect of
Sources
- Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting. (2021) pubmed
- Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice. (2022) pubmed
- Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting. (2015) pubmed
- Netupitant/palonosetron (Akynzeo) for chemotherapy-induced nausea and vomiting. (2015) pubmed
- PMID:30457774 (2018) pubmed
- Netupitant/Palonosetron. (2015) pubmed
- Antiemetics: ASCO Guideline Update. (2020) pubmed
- Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). (2015) pubmed
- PMID:29144698 (2015) pubmed
- Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA). (2020) pubmed